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1. Background 
1.1. Identification and domains of 53BP1  
Using the yeast two-hybrid system, 53BP1 was identified as a protein that binds 
to wild type p53 (Iwabuchi et al., 1994). The 53BP1 gene localizes to 
chromosome 15q15-21 and encodes a protein that is 1972 amino acids long 
(Iwabuchi et al., 1998). A search for protein domains using relatively stringent 
criteria identifies consistently three protein domains: a tudor domain 
(aa1480-1540) and two tandem Brca1 C-terminal (BRCT) domains (aa1714-1850 
and 1865-1972, respectively) (Fig. 1). The BRCT motif is firstly identified in the 
COOH-terminal region of BRCA1 and has been found in a large number of 
proteins involved in various aspects of cell cycle control, recombination, and 
DNA repair in mammals and yeast (Koonin et al. 1996; Bork et al. 1997; 
Callebaut and Mornon 1997; Manke et al., 2003). Evidence suggests that BRCT 
domains may mediate protein–protein interactions (Bork et al., 1997; Zhang et al. 
1998) and in 53BP1, they mediate its interaction with p53 (Iwabuchi et al., 1998). 
The tudor domain is a conserved region of 50 amino acids firstly identified in the 
Tudor protein of Drosophila and found in several proteins involved in binding 
RNA and DNA (Ponting CP, 2004). New evidence suggests that the tudor domain 
containing proteins may associate with methylarginine-containing cellular 
proteins and modify the functions of these proteins (Côté et al., 2005; Kim et al., 
2006). Two recent studies have identified the minimal region of focus formation 
including the conserved tudor domain in 53BP1 (Morales et al., 2003; Goldberg et 
al., 2003), which is critical for 53BP1 location to IR (ionizing radiation)-induced 
foci (Huyen et al., 2004). The 53BP1 tudor domain facilitates an interaction 
between p53 and 53BP1 after DNA damage to promote the localization of 
53BP1-p53 complex to the sites of break and to increase the transcriptional 
activation of p53 (Huang et al., 2007; Kachirskaia et al., 2008).  
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Fig. 1. Schematic diagram of human 53BP1. The functional domains including 
a tudor, a γ-H2AX binding, two BRCT domains, a serine phosphorylated 
residues (S25) and the focus-forming region are indicated.  
 
1.2. Current models regarding 53BP1 function 
1.2.1. The DNA-damage response (DDR) 
DNA damage can be caused by various forms of genotoxic stress, including 
endogenous (reactive oxygen species, abnormal replication intermediates) and 
exogenous (reactive chemicals, UV and IR) sources (Shiloh Y, 2003). DNA 
double-strand break (DSB) is believed to be one of the most serious lesions to 
cells because it can result in loss or rearrangement of genetic information, leading 
to cell death or carcinogenesis. The DNA damage response (DDR) is crucial for 
cellular survival and for avoiding carcinogenesis. This DNA damage can 
stimulate several different components in concert to activate the cellular 
checkpoint that leads to cell cycle delay, DNA repair and programmed cell death 
(Phillips et al., 2007; d'Adda di Fagagna, 2008). These components consist of 
sensors that sense DNA damage, signal transducers that generate and amplify the 
DNA damage signal, effectors that induce cell cycle delay, programmed cell 
death, transcription and DNA repair (Zhou et al., 2000; Phillips et al., 2007; 
d'Adda di Fagagna, 2008) as shown in Fig. 2. 
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Fig. 2. A view of the general outline of the DDR signalling pathway. The 
network of interacting pathways is depicted as a linear pathway consisting of 
signals, sensors, transducers and effectors (Zhou et al., 2000). Arrowheads 
represent activating events and perpendicular ends represent inhibitory events. 
 
1.2.2. 53BP1: focusing on mediating the DDR through ATM 
signalling pathway 
Even though several candidate proteins have been implicated in DNA damage 
response, an official checkpoint-specific damage sensor is still unknown (Phillips 
et al., 2007; d'Adda di Fagagna, 2008). 53BP1 seems to be one of the key-sensors 
of DNA DSBs (Fig. 3), upstream of ATM (ataxia telangiectasia, mutated) (Wang 
et al., 2002; Ward et al., 2003; Zgheib et al., 2005). 53BP1 was found to be a 
nuclear protein that rapidly localizes to discrete foci following DNA damages. 
53BP1 foci may represent “sites of DNA DSBs”, a hypothesis further supported 
by the colocalization of 53BP1 with other proteins known to mark sites of DNA 
DSBs such as phosphorylated histone H2AX (γH2AX) and the 
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Mre11/Rad50/Nbs1 complex (Schultz et al., 2000; DiTullio et al., 2002; Adams et 
al., 2006). The recognition of histone H4 dimethylated at lysine 20 (H4K20me2) 
by the 53BP1 has been shown to be important for 53BP1 localization to at 
chromatin regions flanking the DSBs sites and in broader areas surrounding DSBs 
(Botuyan et al., 2006). Histone lysine methylation has a central role in 
transcriptional regulation and has recently been linked to DNA damage repair. 
Moreover, specific histone methylation and demethylation can both up- and 
downregulate the transcriptional activity of many genes (Sims et al., 2003 and 
2008), suggesting the functions of 53BP1 in the transcription and cell signalling 
response to DNA damages.  
 
ATM and ATR (ATM and Rad3-related) are key molecules in DDR and function 
as essential links between the sensors and effectors of the cellular response to 
DNA damage (Adams et al., 2006). Different studies of 53BP1-deficient cellular 
models indicate that 53BP1 function is tightly correlated with ATM. The interplay 
between ATM and 53BP1 may be direct, on the basis that these two proteins can 
be co-immunoprecipitaed in IR-damaged but not undamaged cells (DiTullio et al., 
2002). Moreover, the recruitment of 53BP1 to γ-H2AX-positive nuclear foci is 
crucial for the phosphorylation of numerous ATM substrates, including p53, 
BRCA1 and the cohesin protein SMC1 (DiTullio et al., 2002; Botuyan et al., 
2006). These effector proteins are responsible for halting cell cycle progression, 
activating transcription, initiating DNA repair mechanisms and triggering 
apoptosis. Interestingly, DDR pathways are not strictly linear and redundant 
signalling occurs. Previous evidence has suggested that 53BP1 may operate both 
upstream and downstream of ATM activation (Mochan et al., 2003; Huyen et al., 
2004).  
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Fig. 3. Schematic representation of the 53BP1-dependent checkpoint 
pathway. The pathway is triggered by IR and other genotoxic events, resulting in 
DNA DSBs. 53BP1 accumulates at or near sites of DSBs, and is important for 
coupling ATM to several of its downstream targets, including p53 (Abraham et al., 
2002). 
 
1.2.3. Function of 53BP1 in Gadd45a signalling pathway 
53BP1 has been functionally linked to p53 as a potential coactivator (Huang et al., 
2007; Kachirskaia et al., 2008). The 53BP1 BRCT tandem repeats were shown to 
bind the DNA-binding domain of p53, though the physiologic context in which 
this interaction functions remains elusive (Adams et al., 2006). Furthermore, the 
tandem tudor domain of 53BP1 recognizes p53 dimethylated at lysine 382 and 
 9
facilitates an interaction between 53BP1 and p53, promoting the accumulation of 
p53 protein and transcriptional activation of p53 at several target genes (Huang et 
al., 2007; Kachirskaia et al., 2008). Subsequent transient co-transfection 
experiments with 53BP1 and p53 reporter plasmids suggested that 53BP1 could 
enhance p53-mediated transcriptional activation (Iwabuchi et al., 1998; 
Kachirskaia et al., 2008). Targeting 53BP1 for knockdown resulted in decreased 
protein levels of p21, p53 upregulated modulator of apoptosis (PUMA) and mdm2 
(Zhang et al., 2006; Huang et al., 2007). 
 
The activated p53, in turn, up-regulates many target genes that may play roles in 
different aspects of cellular response. Gadd45a (the growth arrest and DNA 
damage-inducible gene alpha) is a p53-regulated stress protein (Hollander et al., 
1999). Gadd45a is implicated in the maintenance of genomic fidelity probably via 
its roles in the control of cell cycle G2-M checkpoint (Wang et al., 1999; Zhan et 
al., 1999; Jin et al., 2000), induction of cell death (Takekawa et al., 1998; Harkin 
et al., 1999; Zhan et al., 2002), and DNA repair process (Smith et al., 1994; Smith 
et al., 1996; Hollander et al., 2001). Barreto and his colleagues revealed that 
Gadd45a is a key regulator of active DNA demethylation at global level and it 
acts by promoting DNA repair (Barreto et al., 2007). This work demonstrated 
enhanced demethylation in the presence of overexpressed Gadd45a and XPG 
(xeroderma pigmentosum, complementation group G), a factor involved in NER 
(nucleotide excision repair). 
 
1.3. Epigenetic modification 
The genome contains information in two forms, genetic and epigenetic. The 
genetic information, which is inherited by the DNA replication machinery and 
dictated by the strict rules of Watson and Crick (Szyf et al., 1985), provides the 
blueprint for the manufacture of all the proteins, while the epigenetic information 
provides instructions on how, where, and when the genetic information should be 
used (Szyf et al., 1985). In the post-genomic era of cancer biology, it is becoming 
increasingly evident that epigenetic controls of gene expression play an important 
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role in determining the phenotype of cancer cells, possibly suggesting a novel 
approach and strategy for epigenetically restoring normal phenotype in cancer 
cells (Jones et al., 1999; Reik et al., 2001; Andrew et al., 2004; Esteller M, 2007 
Henikoff S, 2008). Epigenetic is the regulation of changes in gene expression that 
do not involve changes in DNA sequence (Razin et al., 1980). Histone 
modifications and DNA methylation-demethylation events are central to the 
epigenetic regulations of development. The mechanisms controlling these events 
and their dynamic changes have important implications in developmental cell 
biology as well as carcinogenesis and tumor progression (Jones et al., 1999; Reik 
et al., 2001; Andrew et al., 2004; Esteller M, 2007; Henikoff S, 2008). Epigenetic 
technologies in cancer studies are helping increase the number of cancer 
candidate genes and allow us to examine changes in 5-methylcytosine DNA and 
histone modifications at a genome-wide level. In fact, all the various cellular 
pathways contributing to the neoplastic phenotype are affected by epigenetic 
genes in cancer (Andrew et al., 2004; Esteller M, 2007; Jones et al., 2007). They 
are being explored as biomarkers in clinical use for early detection of disease, 
tumor classification and response to treatment with classical chemotherapy 
agents, target compounds and epigenetic drugs. Encouraging results have been 
obtained with histone deacetylase and DNA methyltransferase inhibitors, leading 
the US Food and Drug Administration to approve several of them for the 
treatment of malignancies and lymphoproliferative disorders (Sansom et al., 
2007; Stresemann et al., 2008)  
 
1.3.1. DNA methylation patterns vary in time and space 
DNA methylation is a conserved epigenetic modification of the genome. The 
presence of 5-methylcytosine (5-MeC) in DNA is an epigenetic marker and key 
recognition signal for the regulation of DNA-protein interactions. Methylation of 
cytosines within CpG dinucleotides is associated with transcriptional silencing 
during mammalian development and tumorigenesis (Razin et al., 1980; Jones et 
al., 2002). These dinucleotides are unevenly distributed throughout the genome 
and remain in short stretches or clusters of 500-2000 bp (base pairs), called CpG 
islands (Razin et al., 1980; Jones et al., 2002). CpG methylation plays an 
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important role in maintaining gene silencing that is necessary for tissue- and 
development-specific gene expression, silencing of the inactive X-chromosome, 
genomic imprinting, and protection against the expression of intragenomic 
parasitic elements such as Alu and Line sequences (Jones et al., 1999; Baylin et 
al., 2000; Robertson et al., 2000; Li et al., 2002). During early embryonic 
development, alternating waves of methylation and demethylation have 
programmed cellular growth and differentiation (Li et al., 2002; Haaf et al., 2006). 
The DNA methylation patterns established during this time remain relatively 
stable in normal tissue. Most CpG islands are found in the proximal promoter 
regions of almost half of mammalian genes and are, generally, unmethylated in 
normal cells (Fig. 4). In cancer cells, however, these promoter regions are usually 
hypermethylated, leading to their transcriptional silencing (Baylin et al., 2000; 
Villar-Garea et al., 2003).  
 
 
 
Fig. 4. Methylation patterns of CpG islands in normal and tumor cells. Most 
CpG islands (numerous circles) in the proximal promoter regions surrounding 
and within exon 1 of the sample gene are unmethylated in normal cells (white 
circles) and methylated in tumor cells (black circles) with associated 
transcriptional silencing (red X at the transcription start site) (Baylin et al., 2000).
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1.3.2. DNA methyltransferases (DNMTs) 
Methylation of DNA cytosine is a complex process catalyzed by DNMTs, which 
transfer the methyl group from Sadenosylmethionine (SAM) to generate patterns 
of genomic methylation (Li et al., 1992; Okano et al., 1999; Grønbaek et al., 2007) 
(Fig. 5).  
 
 
 
 
 
Fig. 5. Methylation of cytosine. Cytosine residues in DNA are converted to 
5-methylcytosine by DNMTs. The methyl group is donated by the universal 
methyl donor SAM, which is converted to S-adenosylhomocysteine (SAH) 
(Grønbaek et al., 2007). 
 
 
In mammals, DNMTs can be divided into maintenance (DNMT1) and de novo 
methyltransferases (DNMT3a and DNMT3b) according their functions. During 
DNA replication, the methylation pattern on the parental DNA strand is copied 
onto the newly synthesized strand mainly by DNMT1 (Okano et al., 1999; Bestor 
TH, 2000; Grønbaek et al., 2007) (Fig. 6). However, in early embryonic stem 
cells and cancer cells, methylation of previously unmethylated DNA may occur. 
This so-called de novo methylation is preferentially mediated via DNMT3a and 
DNMT3b (Okano et al., 1999; Bestor TH, 2000; Grønba
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Fig. 6. Establishment and propagation of methylation patterns. De novo 
methylation of previously unmethylated DNA in embryonic stem cells and 
cancer is catalyzed mainly via DNMT3a and DNMT3b. After each replication, 
the methylation pattern of the parental strand is copied onto the newly 
synthesized strand by the maintenance methyltransferase DNMT1 (Grønbaek et 
al., 2007). 
 
DNA methylation is mediated by DNMT family, which encompasses DNMT1, 
DNMT3a and DNMT3b. The importance of these DNMTs in mammalian 
development has been demonstrated in mouse knockout models in which loss of 
DNMT1/DNMT3b or DNMT3 was lethal at the embryonic stage and at four 
weeks after birth, respectively, due to hypomethylation of genomic DNA (Li et 
al., 1992; Okano et al., 1999).  
 
DNA methylation is also strongly implicated in tumorigenesis (Jones et al., 1999; 
Baylin et al., 2000). All three DNMTs, at the mRNA and/or protein level, are 
modestly overexpressed in many types of tumor cells (Robertson et al., 1999; 
DeMarzo et al., 1999). There is considerable evidence indicating an upregulation 
of DNMT1 in cancer (Belinsky et al., 1996; Baylin et al., 1998). Elevated levels 
of DNMT1 are required to silence p16ink4a in bladder cancer cells (Fournel et al., 
1999). Conversely, knock down of DNMT1 in human tumor cells causes 
demethylation and re-activation of tumor suppressor genes (Robert et al., 2003). 
Overexpression of DNMT3a, DNMT3b has also been reported in tumor cells 
(Robertson et al., 1999; Kanai et al., 2001). An increase methylation of DNA in 
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the promoter region of tumor suppressor genes correlates with downregulation of 
transcriptional activation (Schmutte et al., 1998). In addition to transcriptional 
silencing through direct methylation of CpG islands of the promoters, DNMTs 
proteins also have been shown to recruit other transcriptional repressors for this 
purpose (Aapola et al., 2002; Bachman et al., 2003).  
 
1.3.3. The possible link between 53BP1 and DNMTs 
To date, there are several lines of evidence indicating that DNA methylation 
mediated by DNMTs is associated with p53 signalling pathways in maintaining 
genome stability (Wang et al., 2005). The expression of DNMTs was found 
increased in certain cancers and tumor cells with constitutive 53BP1 foci 
(Bartkoval et al., 2005; Gorgoulis et al., 2005). 53BP1 is a central mediator of the 
DNA damage checkpoint and is important for coupling ATM to its downstream 
targets including p53 and Gadd45 (Wang et al., 2002; Adams et al., 2006). The 
interaction between 53BP1 and p53 facilities the stabilization of p53 protein and 
enhances p53-mediated transcriptional activation (Zhang et al., 2006; Huang et 
al., 2007; Kachirskaia et al., 2008). Furthermore, 53BP1-null mice eventually 
succumb to genomic instability and cancer development in a p53-dependent 
manner (Celeste et al., 2003; Ward et al., 2005; Morales et al., 2006). Recent 
studies have demonstrated that DNMT1- and DNMT3a-mediated methylation is 
stimulated by p53, suggesting cooperation between p53 and DNMTs in the 
regulation of gene methylation (Wang et al., 2005; Lai et al., 2008). Taken 
together, these observations implicate the possible functions of 53BP1 in 
regulating the DNMTs. 
 
1.3.4. DNA demethylation 
In contrast to the large amount of information accumulated on DNA methylation, 
relatively little is known about DNA demethylation. The DNA demethylation can 
be either passive or active, or a combination of both. Passive DNA demethylation 
occurs by inhibition or lack of maintenance of DNMTs throughout cycles of 
replication, whereas active DNA demethylation requires specific enzymatic 
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reactions (Kress et al., 2001; Bird, 2002; Patra et al., 2008). Active demethylation 
occurs during early development and differentiation. These mechanisms can 
explain active demethylation without mitotic process (Szyf et al., 1985; Kafri et 
al., 1993; Weiss et al., 1996). Recent studies suggested that DNA methylation 
pattern is a steady-state balance of methylation and demethylation (Fig. 7). In 
contrast to the classic model, DNA methylation pattern is in a dynamic steady 
state of methylation and demethylation catalyzed by DNMTs and demethylases 
(Szyf et al., 2005, Patra et al., 2008).  
 
 
 
 
Fig. 7. The DNA methylation pattern is a steady-state balance of methylation 
and demethylation. Interaction of trans-acting repressors (TR) recruits histone 
modification enzymes such as histone deacetylases (HDAC) and histone 
methyltransferases (HMTASE) to specific genes. HDACs and HMTASE in turn 
recruit DNMTs and methylated DNA binding proteins such as MeCP2 to tilt the 
balance of the reaction toward DNA methylation. Trans-acting activating factors 
(TAF) on the other hand recruit histone acetyl transferases (HAT) to specific 
genes. The presence of HATs results in acetylation of histones and increased 
accessibility to demethylases tilting the steady state balance of the DNA 
methylation equilibrium toward demethylation (Szyf et al., 2005). 
 16 
1.3.5. DNA demethylases 
Although three active demethylation mechanisms have been proposed, none of 
them has gained wide acceptance (Kress et al., 2001). The first mechanism is 
direct replacement of the methyl moiety by a hydrogen atom. Several lines of 
evidence have been provided MBD2 as a demethylase by this mechanism: 1) 
exogenous expression of MBD2 increased replication-independent active 
demethylation of ectopically methylated DNA (Cervoni et al., 2001) and resulted 
in overexpression of the urokinase type plasminogen activator and the hexokinase 
type II by demethylation of their hypermethylated promoters in vitro (Guo et al., 
2002; Goel et al., 2003); 2) antisense inhibition of MBD2 reduced 
replication-independent active demethylation (Detich et al., 2003); 3) recombinant 
MBD2 expressed and purified from A549 cells has been shown to possess 
demethylase activity in vitro (Detich et al., 2003). The second mechanism 
implicates a role for DNA glycosylases, which cleave the bond between the 
5-methylcytosine base and the deoxyribose moiety in DNA. The abasic site is 
then repaired by resident repair activity resulting in replacement of a 
5-methylcytosine with an unmethylated cytosine (Goel et al., 2003; Jost et al., 
1995 and 1997). The third mechanism describes the methylated nucleotide as 
being removed by nucleotide excision, being replaced by an unmethylated 
cytosine (Weiss et al., 1996 and 1997). Nucleotide excision repair is an important 
mechanism for removing a wide spectrum of different DNA lesions, which can 
repair damaged DNA during DNA replication (David et al., 2007). Cells may use 
this repair processes as buffer, as additional localized demethylation pathways for 
gene transcription. Recent studies have demonstrated that the nucleotide excision 
mechanism induced the local targeted DNA demethylation by a transcriptional 
activator during development in living cells (Kapoor et al., 2005; Kress et al., 
2006; Murayama et al., 2006). It has been proposed that Gadd45a, the target gene 
of p53, can catalyze active demethylation through this mechanism (Barreto et al., 
2007). 
 17 
1.4. RASSF1A and C1S2 repeats in A549 cells 
The small GTP-binding protein Ras plays an important role in mediating multiple 
intracellular signal transductions, including growth, apoptosis, and differentiation 
(Vavvas et al., 1998; Khokhlatchev et al., 2002). RASSF1A (Ras association 
domain family 1 isoform A), a candidate tumor suppressor gene, contains the 
Ras-association domain that interacts with Ras and mediates K-Ras-dependent 
apoptosis (Vos et al., 2000; Donninger et al., 2007). Transcriptional silencing of 
RASSF1A by promoter methylation has been found in many types of carcinomas 
and tumor cells including human lung adenocarcinoma cell A549 that exhibits 
K-Ras activating mutation (Beaulieu et al., 2002; Dammann et al., 2005a). Recent 
study in non-small cell lung cancers demonstrated that RASSF1A methylation, in 
combination with K-ras mutation, might have an adverse synergistic effect on 
patient’s survival (Kim et al., 2003). Re-expression of RASSF1A in various 
tumor cells where this gene is deleted or its promoter is methylated inhibits cell 
growth, invasion, stimulates apoptosis and reduces tumorigenicity in mouse 
models (Dammann et al., 2000; Donninger et al., 2007).  
 
Repetitive sequences like Alu elements, α- and classic satellite DNA are strongly 
methylated in the human genome (Jeanpierre M 1994). Satellite 2 (Sat2) DNA 
sequences are found predominantly in juxtacentromeric heterochromatin of 
certain human chromosomes and are most abundant in the long juxtacentromeric 
heterochromatin region of chromosome 1 (Ehrlich et al., 2003). The chromosome 
1 satellite 2 (C1S2) is methylated highly in diverse cell lines and has been used as 
marker for the analysis of the global methylation (Ehrlich et al., 2003; Mund et al., 
2005; Wilson et al., 2007).  
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1.5. The aim of this study 
Epigenetic silencing by hypermethylation of CpG islands in the promoter regions 
of tumor-suppressor genes is involved in the initiation and progression of several 
types of cancer (Baylin et al., 2000; Esteller M, 2007). DNA methylation changes 
in cancer represent innovative diagnostic markers and attractive therapeutic 
targets by using demethylating agents (Yoo et al., 2006; Stresemann et al., 2008). 
However, the mechanisms of DNA demethylation in regulation of gene 
expression are still unknown. 53BP1 has been suggested as a sensor and/or 
mediator of the DNA damage checkpoint. 53BP1 function is important for 
coupling ATM to its downstream targets including p53 and Gadd45. The latter 
has been reported to participate to active demethylation (Barreto et al., 2007). In 
light of these findings, we hypothesize that: 
 
(1) 53BP1 may play an important role in DNA demethylation in cellular response 
to DNA damage to protect genomic stability. 
 
(2) 53BP1 signalling is associated with DNMTs in maintaining genome stability. 
 
(3) The possible mechanisms of 53BP1 in regulation of DNA demethylation may 
be involved in the activation of Gadd45a and MBD2. 
 
The purpose of the present dissertation was to clarify the role of 53BP1 in DNA 
demethylation as a response to DNA damage. In order to determine the 
relationship between the overexpression of 53BP1 and the methylation status of 
DNA, the methylation status of the RASSF1A gene and C1S2 DNA repetitive 
elements was assessed in A549 cells transfected with different 53BP1 plasmids 
by methylation specific PCR (MSP) and combined bisulfite restriction analysis 
(COBRA). The expression of RASSF1A gene in A549 cells transfected with 
different 53BP1 plasmids by RT-PCR was also investigated. Additionally, the 
effect of 53BP1 on the expression of DNMTs, Gadd45a, and MBD2 was 
evaluated by quantitative real-time PCR.  
 19 
2. Materials 
2.1. Plasmid used in this study 
The expression plasmids of full-length cDNA (pCMH6K-53BP1), N-terminal 
1052 (pCMH6K-53BP1N) and C-terminal 921 residues (pCMH6K-53BP1C) of 
53BP1 were kindly provided by Kuniyoshi Iwabuchi, M.D., Ph.D., Associate 
Professor, Department of Biochemistry, Kanazawa Medical University, Japan 
(Iwabuchi et al., 1998). The β-galactosidase (β-gal) -encoding plasmid 
pcDNA3.1/His/lacZ used to monitor transfection efficiency was purchased from 
Invitrogen (Kalrsruhe, Germany). The maps of these plasmids were displayed 
under below (Fig. 8A and 8B). 
 
pCMH6K 
4170 bp
ATG HA 53BP1
53BP1N
53BP1C
6.2 kb
3.3 kb
3.1 kb
BamHI BglII
 
Fig. 8A. The full-length cDNA (6.2 kb), N-terminal (53BP1N, 3.3 kb) and 
C-terminal (53BP1C, 3.1 kb) of 53BP1 were constructed in the vector pCMH6K 
containing an influenza virus hemagglutinin (HA) tag at the N-terminal. Pcmv: 
CMV promoter, ATG: ATG initiation codon, BGH pA: BGH polyadenylation 
signal, Psv40: SV40 promoter and origin, Neomycin: neomycin resistance gene, 
Ampicillin: ampicillin resistance gene. 
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Fig. 8B The map of β-gal-encoding plasmid pcDNA3.1/His/lacZ was taken from 
Invitrogen, Germany. Pcmv: CMV promoter, ATG: ATG initiation codon, BGH 
pA: BGH polyadenylation signal, Psv40: SV40 promoter and origin, SV40 pA: 
SV40 polyadenylation signal, Neomycin: neomycin resistance gene, Ampicillin: 
ampicillin resistance gene. 
 
 
2.2. Cell line 
The human lung adenocarcinoma cell line A549 and cervix adenocarcinoma cell 
line Hela were purchased from the American Type Culture Collection (Manassas, 
VA). Cells were cultured at 37°C in RPMI 1640 medium supplemented with 1% 
penicillin/streptomycin (Sigma, Germany) and 10% fetal calf serum (FBS) 
(Sigma, Germany). 
 
2.3. Primers 
Table. 1. Primer sequences and PCR conditions 
Gene  Forward Reverse Annealing  Product 
 
Reference 
  primer(5'-3') primer(5'-3') (cycles) size(bp)  
 
Reverse transcription PCR     
 
  RASSF1A CAGATTGCAAGTTCACCTGCCACTA GATGAAGCCTGTGTAAGAACCGTCCT 60(37cy) 244 Dote et al., 2005 
  53BP1-N AGGTGGGTGTTCTTTGGCTTCC TTGGTGTTGAGGCTTGTGGTGATAC 60(37cy) 328 Kao et al., 2003 
  53BP1-C GCAGCCTCTGTGAAGCAGCA ATGCAAGGAATCCAGTTACACACAA 60(37cy) 303 Gorgoulis et al., 2005 
  GAPDH TGGTCACCAGGGCTGCTT AGCTTCCCGTTCTCAGCCTT 55(35cy) 150 Bussolati et al., 2005 
 
Real time PCR     
 
  Gadd45a TCAGCGCACGATCACTGTC CCAGCAGGCACAACACCAC 58(37cy) 82 Kis et al., 2006 
  MBD2 AACCCTGCTGTTTGGCTTAAC CGTACTTGCTGTACTCGCTCTTC 58(40cy) 101 Fang et al., 2003 
  DNMT1 ACCGCTTCTACTTCCTCGAGGCCTA GTTGCAGTCCTCTGTGAACACTGTGG 60(40cy) 329 Mizuno et al., 2001 
  DNMT3a CACACAGAAGCATATCCAGGAGTG AGTGGAAACCAAATACCC 60(40cy) 550 Mizuno et al., 2001 
  DNMT3b AATGTGAATCCAGCCAGGAAAGGC ACTGGATTACACTCCAGGAACCGT 60(40cy) 191 Mizuno et al., 2001 
     
Methylation-specific PCR      
  RASSF1A M: GTGTTAACGCGTTGCGTATC M: AACCCCGCGAACTAAAAACGA 60(40cy) 93 Lo et al., 2001 
 U: TTTGGTTGGAGTGTGTTAATGTG U: CAAACCCCACAAACTAAAAACAA 60(40cy) 105 Lo et al., 2001 
 
COBRA PCR     
 
  C1S2 ATGGAATTTTTATGAAATTGAAATG CATTCCATTAAATAATTCCATTC 51(40cy) 210 Mund et al., 2005 
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2.4. Chemicals 
ABsolute SYBR Green Mixes ABgene, Germany 
Acrylamide stock 30% Roth, Germany 
Agarose Sigma Aldrich, Germany 
Ampicillin PAA, Germany 
Boric acid Sigma Aldrich, Germany 
CoCl2 Sigma Aldrich, Germany 
DNase I, RNase-free Fermentas, Germany 
Distilled water Millipore, Germany 
dNTPs Fermentas, Germany 
EDTA AppliChem, Germany 
Ethanol 100% Roth, Germany 
FastDigest™ buffer Fermentas, Germany 
FastDigest™ HinfI Fermentas, Germany 
GeneRuler 100bp DNA ladder Fermentas, Germany 
Glycerol (absolute) AppliChem, Germany 
Hot-star Taq-polymerase Qiagen, Germany 
Hydroquinone Sigma Aldrich, Germany 
L-glutamine PAA, Germany 
6x loading dye solution Fermentas, Germany 
MgCl2 Fermentas, Germany 
M-MuLV reverse transcriptase Fermentas, Germany 
NaCl Sigma Aldrich, Germany 
NaOH Sigma Aldrich, Germany 
PBS buffer PAA, Germany 
Penicillin/streptomycin PAA, Germany 
Puromycin dihydrochloride Sigma Aldrich, Germany 
Roti-fect plus Roch, Germany 
RPMI 1640 medium PAA, Germany 
Sodium bisulfite Sigma Aldrich, Germany 
Taq-polymerase Fermentas, Germany 
TEMED Carl Roth chemical, Germany 
Tris base Sigma Aldrich, Germany 
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Trypan blue stain (0.4%) Sigma Aldrich, Germany 
Trypsin/EDTA Invitrogen, Germany 
Tryptone Sigma Aldrich, Germany 
Xylene cyanole Sigma Aldrich, Germany 
Yeast extract Sigma Aldrich, Germany 
 
2.5. Experiment Kits 
First Strand cDNA synthesis kit Fermentas, Germany 
ß-gal staining kit Invitrogen, Germany 
Nucleospin extract II Machery-Nagel, Germany 
DNeasy blood & tissue kit Qiagen, Germany 
Plasmid midi kit Qiagen, Germany 
RNeasy mini kit Qiagen, Germany 
 
2.6. Reagents 
Competent Cells 
 
MAX Efficiency® DH5α™ Competent Cells, Invitrogen, Germany 
 
Luria-Bertani (LB) ampicillin liquid medium (store at 4°C): 
Dissolve the following in 800 ml distilled H2O 
NaCl 10 g 
Tryptone 10 g 
Yeast extract 5 g 
Adjust the pH to 7.0 with 1 M NaOH 
Adjust the volume to 1000 ml  
Sterilize by autoclaving 
Add ampicillin 100 mg/ml stock to 100 µg/ml final concentration 
Transfer medium to plate 
 
Cell culture medium: 
RPMI 1640 PAA, Germany 
10% Fetal bovine serum (FBS) Sigma, Germany 
1% Penicillin/streptomycin PAA, Germany 
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10 mM hydroquinone: 
Hydroquinone 11 mg 
Dissolve in 5 ml distilled water 
Add up to 10 ml 
 
40.5% or 3.9 M sodium bisulfite: 
Sodium bisulfite 2.835 g 
Dissolve in 4 ml distilled water 
Adjust pH to 5.0 with 3 M NaOH 
Add the volume to 7 ml 
 
3 M NaOH: 
NaOH 1.199 g 
Dissolve in 5 ml distilled water 
Add up to 10 ml 
 
1x PBS: 
Dissolve the following in 800 ml of distilled H2O 
NaCl 8 g 
KCl 0.2 g 
Na2HPO4 1.44 g 
KH2PO4 0.24 g 
Adjust the pH to 7.4 with HCl and add H2O to 1 liter  
 
12% polyacrylamide solution: 
30% Acrylamid stock solution 6 ml 
Distilled water 5.9 ml 
5x TBE 3 ml 
10% Ammonium persulfite 0.1 ml 
TEMED 10 µl  
 
5x TBE buffer (store at room temperature): 
Dissolve the following in 800 ml distilled H2O 
Tris 54 g 
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Boric acid 27.5 g 
0.5M EDTA 20 ml 
Adjust the volume to 1000 ml 
 
TE buffer: 
1M Tris-HCl (pH7.5) 10 ml 
0.5M 2 ml EDTA (pH8.0) 
Add H2O to 1 liter  
 
2.7. Consumables 
Cell culture flasks 25 cm2 Nunclon™, Denmark 
Distilled water Millipore, Germany 
1.5 ml Eppendorf centrifuge tube Eppendorf, Germany 
Polypropylene tube FALCON®, NJ, USA 
6-well flat bottom culture plate Nunclon™, Denmark 
10 µl white tips Roth, Germany 
200 µl yellow tips Roth, Germany 
1000 µl blue tips Roth, Germany 
 
2.8. Apparatus 
37°C CO2 incubator Heraeus, Germany 
Heating block VWR, Germany 
MyQ thermal cycler Bio-Rad, USA 
Laminar flow cabinet Heraeus, Germany 
Elekta SL-25 linear accelerator Norcross, GA 
Pipettes Eppendorf, Germany 
-20°C Refrigerator Bosch, Germany 
-80°C Refrigerator Bosch, Germany 
Shaking incubators Heraeus, Germany 
Table centrifuge Heraeus, Germany 
UV spectrophotometer Bio-Rad, USA 
Water bath Lauda, Germany 
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3. Methods 
3.1. Bacterial transformation and plasmid recovery 
3.1.1. Bacterial transformation with plasmid DNA  
Plasmid DNA was transformed into MAX Efficiency® DH5α™ Competent Cells 
according to the manufacturer’s instructions (Invitrogen, Germany). Briefly, 50 µl 
of competent E. coli cells were added to each pre-chilled tubes. 5 ng of plasmid 
DNA was added to the tubes. After incubation on ice for 30 min, the cells were 
heat shocked for 45 s in a water bath at 42°C. The tubes were returned to ice for 2 
min. After adding 450 µl of LB medium, the tubes were incubated for 1 h at 37°C 
with shaking (150 rpm). 100 µl of each solution was spread onto LB plates 
containing 100 µg/ml ampicillin (PAA, Germany). The plates were incubated 
overnight at 37°C. Then a single colony was picked from the above plate and 
inoculated into a tube containing a starter culture volume of 5 ml of LB medium. 
The tubes were incubated for 8 h at 37°C with vigorous shaking (300 rpm). 50 µl 
of starter culture was diluted into the tubes containing 25 ml of LB ampicillin 
medium. The tubes were incubated at 37°C for 16 h with vigorous shaking (300 
rpm). 
 
3.1.2. Plasmid DNA recovery 
The bacterial cells were harvested by centrifugation (8000 rpm) for 15 min at 4°C. 
The supernatant was discarded and the bacterial pellet was resuspended in 4 ml of 
buffer P1 from the Plasmid midi kits (Qiagen, Germany). After adding 4 ml of 
buffer P2 and mixing by vigorously inverting the sealed tube 4 times, the tube 
was incubated at room temperature for 5 min. Following adding 4 ml of chilled 
buffer P3 and mixing immediately by vigorously inverting 4 times, the tube was 
incubated on ice for 15 min. Centrifugation was performed at 13000 rpm for 30 
min at 4°C. The supernatant containing plasmid DNA was removed and 
centrifuged again at 13000 rpm for 15 min at 4°C.  The supernatant was loaded 
onto an equilibrated QIAGEN-column and allowed it to enter the resin by gravity 
flow. The QIAGEN-column was washed twice with 10 ml of buffer QC. The 
plasmid DNA was eluted with 5 ml of buffer QF and precipitated by adding 3.5 
ml of isopropanol at room temperature. The mixture was centrifuged immediately 
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at 13000 rpm for 30 min at 4°C. The supernatant was decanted and the pellet was 
washed with 2 ml of 70% ethanol. After centrifugation at 13000 rpm for 10 min, 
the supernatant was decanted. The purified DNA was re-dissolved in 100 µl of 
TE buffer (pH 8.0). The concentration and purity of DNA were determined 
spectrophotometrically, and required an A260/280 ratio of at least 1.8. 
 
3.2. Cell culture  
3.2.1. Thawing cultured cells 
A549 cells stored in liquid nitrogen were thawed quickly in a water bath (37°C). 
The cells were transferred to a sterile 15ml tube containing prewarmed RPMI 
1640 medium supplemented with 10% FBS and 1% penicillin-streptomycin. 
Following centrifugation at 1200 x g for 5 min, the cells were resuspended in 
T-25 cm2 flask containing 5 ml prewarmed RPMI 1640 medium. The flasks were 
incubated overnight at 37°C in a humidified 5% CO2 incubator. After a few days, 
cells grew into the gaps of the flasks, and reached confluence.  
 
3.2.2. Subculturing cells 
After trypsinizing the cells with trypsin solution, the floating cells were 
transferred to a centrifuge tube. Following centrifugation at 1200 x g for 7 min, 
the cells were resuspended in fresh growth media and seeded into a new flask. A 
subcultivation ratio was 1:5. The medium was re-placed 2 to 3 times per week.  
 
3.2.3. Treatment of cells with CoCl2 
A549 cells (5 x 105) were grown in a T-25 cm2 flask at 37°C in a humidified 5% 
CO2 incubator After 24 h, the cells were replaced with prewarmed RPMI 1640 
medium with and without CoCl2 (100 µM) and cultured for 5 days to induce 
hypoxia. The cells were collected for DNA-isolation and methylation analysis. 
 
3.3. Cell transfection  
A549 cells (5 x 105) were grown in a T-25 cm2 flask at 37°C in a humidified 5% 
CO2 incubator for 24 h until they are 70% confluent and transfected with 53BP1 
expression plasmids by using the Roti-fect plus transfection reagent. Briefly, the 
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following solutions were prepared in polystyrene tubes: A) 4 µg of plasmid DNA 
(pCMH6K-53BP1, pCMH6K-53BP1N, pCMH6K-53BP1C, pcDNA3.1, and 
pcDNA3.1/His/lacZ, respectively) in 300 µl of serum-free medium without 
antibiotics. B) 16 µl of Roti-fect plus solution in 300 µl of serum-free medium 
without antibiotics. Both solutions were mixed gently by pipetting several times 
and combined together. After incubating at room temperature for 15 min, the 
nucleic acid-lipid complex was added to the cells. The flask was rocked gently in 
order to evenly disperse the complex mixture. The medium was replaced 1 day 
later and the cells were harvested 72 h post transfection. The experiments were 
performed in triplicate.  
 
3.3.1. Determination of transfection efficiency with ß-gal staining  
At 24 h after transfection, the cells were stained to determine the transfection 
efficiency using the β-gal staining Kit (Invitrogen, Germany). LacZ is a bacterial 
gene often used as a reporter construct in eukaryotic transfection experiments 
because the gene product, β-gal, is resistant to proteolysis in cellular lysates and 
its activity is easily assayed. The β-gal enzyme catalyzes the hydrolysis of X-gal 
(5-bromo-3-indoyl-β-D-galactopyranoside).  Following fixation and incubation 
with the X-gal substrate, cells transfected with a β-gal-expressing plasmid will 
appear blue. Briefly, the growth medium was removed from the cells transfected 
with plasmid pcDNA3.1/His/lacZ. After rinsing the flask with 2.5 ml of PBS, the 
cells were fixed using 1 x fixative solution for 10 min at room temperature. While 
the flask was in the fixative solution, the staining solution containing 25 µl of 
solution A, 25 µl of solution B, 25 µl of solution C, 125 µl of 20 mg/ml X-gal in 
DMF, and 2.3 ml of PBS was prepared in a polypropylene tube according to the 
manufacturer’s protocol (Invitrogen, Germany). Staining solution was added to 
the flask after rinsing twice with 2.5 ml of PBS. The cells were incubated at 37°C 
overnight and observed under a microscope. For each flask, five visual fields were 
chosen randomly under 20X magnification. Cells stained blue were counted and 
the transfection efficiency was calculated as the percentage of the blue cells in 
each field. 
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3.4. IR of A549 cells following transfection 
The cells were irradiated at 4, 6 and 10 Gy using a 6 MV Elekta SL-25 linear 
accelerator of 450 cGy/min at 24 h after transfection. 
 
3.5. DNA isolation 
The isolation of genomic DNA from cells was performed by using DNeasy Blood 
& Tissue Kit (Qiagen, Germany) according to the manufacturer’s protocol. The 
cells grown in culture flasks were trypsinized, harvested and resuspended in 200 
µl of PBS. After digestion with 20 µl of proteinase K, the cell pellet was 
incubated with 200 µl of buffer AL at 56°C for 10 min. This was followed by 
three times washing with 200 µl of 100% ethanol, 500 µl of buffer AW1, and 500 
µl of buffer AW2, respectively. The genomic DNA was precipitated and eluted in 
200 µl of buffer AE by centrifugation for 1 min at 13000 rpm. The quality and 
concentration of isolated DNA were determined spectrophotometrically, and 
required an A260/280 ratio of at least 1.8. 
 
3.6. RNA isolation 
Total RNA was isolated from each sample using RNeasy Mini kit (Qiagen, 
Germany) according to the manufacturer’s instruction. In brief, the cell pellet was 
disrupted by adding 350µl of buffer RLT. The lysate was homogenized and 
pipetted directly into a QIAshredder spin column placed in a 2 ml collection tube. 
After centrifugation for 2 min at full speed, 1 volume of 70% ethanol was added 
to the homogenized lysates. 700 µl of the sample was transferred to the RNeasy 
spin column placed in a 2 ml collection tube. After centrifugation for 15 s at 
13000 rpm, the flow-through was discarded. This was followed by three times 
washing with 700 µl of buffer RW1 and twice washing with 500 µl of buffer RPE 
for 15 s. The RNeasy spin column was replaced in a new 1.5 ml collection tube. 
The RNA was eluted in 50 µl of RNase-free water by centrifugation for 1 min at 
13000 rpm. The quality and concentration of the RNA were determined 
spectrophotometrically, and required an A260/280 ratio of at least 1.8. All RNA 
samples were subjected to DNase I (Fermentas, Germany) digestion for 30 min at 
37°C in order to prevent genomic DNA contamination. 
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3.7. cDNA synthesis 
First strand cDNA was synthesized using cDNA synthesis kit (Fermentas, 
Germany). Briefly, one microgram of total RNA was used for synthesis reaction 
containing 1 µl of oligo(dT)18 primer (0.5 µg/µl) and then was added 
DEPC-treated water to volume of 11 µl. The reaction mixes were incubated at 
70°C for 5 min and chilled on ice. After adding the following components in the 
indicated order: 4 µl of 5 x reaction buffer, 1 µl of RiboLock™ ribonuclease 
inhibitor (20 U/µl), 2 µl of 10 mM dNTP mix, the reaction mixes were incubated 
at 37°C for 5 min. After adding 2 µl of M-MuLV reverse transcriptase (20 U/µl), 
the reaction mixes were incubated at 37°C for 60 min. The reaction was 
inactivated by heating at 70°C for 10 min and chilled on ice. The synthesized 
cDNA was diluted 6-fold prior to PCR amplification.  
 
3.8. Reverse transcription-polymerase chain reaction (RT-PCR) 
The primers used in PCR reactions were summarized in Table 1. Briefly, 
RT-PCR reaction mixture contained 5 µl of diluted cDNA, 1.0 unit Tag-DNA 
polymerase, 1.5 mM MgCl2, 0.2 mM of each dNTP, and 5 pmol of each primer. 
PCR reaction conditions consisted of 30 s at 94°C, 30 s at anneal temperature and 
1 min at 72°C for 35 cycles post initial 30 s denaturation at 94°C, and a final 
extension for 3 min at 72°C. The house keeping gene glyseraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as internal reference to standardize the 
amount of cDNA. The PCR products (20µl) were resolved on 2% TBE agarose 
gels at 60V/cm for 1 h together with a 100bp marker and visualized after 
ethidium bromide-staining under UV illumination. 
 
3.9. Quantitative real-time PCR  
Quantitative real time PCR was carried out using SYBR Green PCR Master Mix 
(Abgene, UK) following manufacturer’s instruction. Briefly, 5 µl of diluted 
cDNA was added to a total volume of 25 µl containing 12.5 µl of 2 x SYBR 
Green Master Mix and 0.2 µmol/L of each primer. The primer sequences, 
annealing temperatures, and expected PCR product size were summarized in 
Table 1. The PCR reaction was performed with 40 cycles of 30 s at 95°C, 30 s at 
anneal temperature, and 1 min at 72°C, post an initial denaturation of 15 min at 
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95°C. Fluorescence data was recorded at the end of each 72°C step using an 
iCycler apparatus (Bio-Rad). After the final cycle, melting curve analysis of all 
samples was conducted within the range from 58-95°C. Relative quantification of 
gene expression was performed by using GAPDH as an internal control. The 
threshold cycle and the 2-∆∆Ct method were used for calculating the relative 
amount of the target RNA (Saha et al., 2001). Gene expression was firstly 
normalized relative to GAPDH within the same sample, and then treatment group 
expression was calculated by setting the controls as 100%. The quantitative 
real-time PCR was performed at least three times and always included a 
no-template sample as a negative control. For experimental comparisons, genes 
showing at least a 2-fold change were identified.  
 
3.10. Bisulfite modification of genomic DNA and methylation 
analysis 
3.10.1. Bisulfite modification of genomic DNA 
Bisulfite treatment of DNA converts of unmethylated cytosine into uracil while 
methylcytosine remains unchanged. Bisulfite modification of genomic DNA was 
performed as described (Herman et al 1996). Briefly, 3 µg of genomic DNA was 
resuspended in 66.5µl of distilled water and denatured with 3.5 µl of 3 M NaOH 
at 50°C for 10 min, followed by incubation with 510 µl of 3.9 M sodium bisulfite 
(Sigma, Germany) and 30 µl of 10 mM hydroquinone (Sigma, Germany) at 55°C 
for 16 h in darkness. Afterward, modified DNA was purified using the Macherey 
DNA purification resin (Machery-Nagel, Germany). Briefly, 2 volume of 
NT-buffer was added to the bisulfite-modified DNA and the mixture was pipetted 
onto NucleoSpin Exact II column. After centrifugation at 9.7 rpm for 1 min, 610 
µl of NT3 buffer was added to the column. After centrifugation at 9700 rpm for 1 
min, the genomic DNA was eluted in 50 µl of TE buffer and stored at -20°C until 
ready for use. 
 
3.10.2. Combined bisulfite restriction analysis (COBRA) of C1S2 
COBRA is a sensitive and quantitative DNA methylation assay that combinates 
bisulfite treatment of DNA and PCR amplification followed by restriction 
digestion (Xiong et al., 1997). The methylation status of C1S2 elements in 
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transfected cells was determined by COBRA as previously described (Xiong et al., 
1997). Briefly, 8 µl of the bisulfite-modified DNA was added in 50 µl reaction 
volume containing 2.5 mM MgCl2, 0.2 mM of each dNTP, 1 x PCR reaction 
buffer, 5 pmol of each primer and 2.0 units of Hot-star Taq-DNA polymerase 
(Qiagen, Germany). The primer sequences for C1S2 used in this study are listed 
in Table 1. PCR was carried out using the following cycling conditions: 
denaturation at 95°C for 15 min, 40 cycles (95°C for 30 s, 51°C for 30 s, and 
72°C for 30 s), and a final extension of 72°C for 10 min. The PCR product was 
further digested with FastDigest™ HinfI restriction enzyme (Fermentas, 
Germany), which recognizes only methylated CpG sequences. Briefly, 1 µl of 
FastDigest™ HinfI and 5 µl of 10 x fast digest FastDigest™ buffer were added to 
PCR products. The tube was incubated at 37°C for 20 min. The reaction was 
inactivated at 65°C for 20 min. Digested PCR products were separated by 
electrophoresis on 8% polyacrylamide gels. The gels were then stained with EB 
and visualized under UV illumination. 
 
3.10.3. Methylation specific PCR (MSP) 
The MSP is a simple, sensitive, and specific PCR method for determining the 
methylation status of virtually any CpG-rich region with primers specific for 
methylated versus unmethylated DNA (Herman et al., 1996). The methylation 
status of the RASSF1A promoter regions was determined by using MSP as 
previously described (Herman et al., 1996). PCR primers that distinguish between 
the methylated and unmethylated DNA sequence were used (Table 1). Negative 
controls without DNA were included for each set of PCR. Briefly, 8 µl of 
bisulfite-modified DNA was amplified in a final volume of 25 µl containing 1 x 
PCR reaction buffer (Qiagen, Germany), 1.5 mM MgCl2, 0.2 mM of each dNTP, 
5 pmol of each primer and 1.0 unit of Hot-Star Taq-DNA polymerase (Qiagen, 
Germany). PCR was carried out at 95°C for 15 min, 40 cycles of 95°C for 30 s, 
the specific annealing temperature for 30 s and 72°C for 30 s, followed by a final 
extension of 72°C for 10 min. PCR products were loaded onto 8% polyacrylamide 
gels and visualized after ethidium bromide-staining under UV illumination. 
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4. Results 
4.1. Establishment of cell lines with overexpression of 53BP1  
To assess the biological relevance of 53BP1 on the active demethylation of DNA, 
A549 cells were transiently transfected with the different expression vectors of 
53BP1 or control vector pcDNA3.1.. Because patterns of DNA methylation were 
regulated during chromatin remodeling and cell division (Meehan et al., 2001; 
Stirzaker et al., 2004) and the double time of A549 cells was about 42 h 
(www.atcc.org), we monitored transfection efficiencies of A549 cells at 24 h after 
transfection and analysed the effects of exogenous expression of 53BP1 on DNA 
demethylation at 3 days after transfection as described previously (Tawa et al., 
1998). The transfection efficiencies at 24 h after transfection assessed by counting 
of ß-gal–stained cells were from 50 to 60%, approximately. One representative 
example of the ß-gal staining was shown in Fig. 9. 
 
        
 
 
Fig. 9. The expression of ß-gal in A549 cells transfected with the plasmid 
pcDNA3.1/His/lacZ. The positive cells showed blue pattern after X-gal staining.  
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We performed real time PCR to detect the transcriptional level of 53BP1 in A549 
cells at 3 days after transfection. In comparison with control, the induced 
expressions of 53BP1 were 374-fold, 89-fold and 98-fold in A549 cells 
transfected with full-length, N- and C-terminal of 53BP1 analysed by real time 
PCR, respectively. The expression 53BP1 and the specificity of PCR products 
were confirmed by RT-PCT (Figure 10).  
 
        
Fig. 10. Expression of 53BP1 in transfected A549 cells. The A549 cells were 
transfected with different expression plasmids of 53BP1 or control plasmid. The 
amplified PCR products were visualized on a 2% agarose gel. GAPDH served as 
endogenous control. 53BP1-N’, primers located on N-terminal; 53BP1-C’, 
primers located on C-terminal. M, 100 bp marker; Full, cells transfected with 
full-length of 53BP1; N, cells transfected with N-terminal of 53BP1; C, cells 
transfected with C-terminal of 53BP1; Con, cells transfected with control plasmid 
pcDNA3.1. 
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4.2. Establishment of COBRA method  
Alteration in oxygenation status can induce DNA demethylation (Panayiotidis et 
al., 2004). CoCl2 has been widely to mimic hypoxia both in vivo and in vitro 
studies (Wang et al., 1993). To establish COBRA for determination of the DNA 
methylation status of C1S2 repeats, A549 cells were incubated with CoCl2 (100 
µM) to induce hypoxia for 5 days as described (Wang et al., 1993; Shahrzad et 
al., 2007). As shown in Fig. 11A, the CpG dinucleotides in C1S2 were mainly 
methylated in untreated A549 cells. In contrast, CoCl2 treatment for 5 days 
resulted in an increase in the level of unmethylated CpG dinucleotides. In line 
with previous study (Shahrzad et al., 2007), these data indicate that chemically 
induced hypoxia can promote demethylation of repetitive elements. Meanwhile, 
IR is also known to alter the DNA methylation in vivo and in vitro (Kalinich et 
al., 1989; Tawa et al., 1998; Koturbash et al., 2005). Kalinich et al. showed that 
different doses of X-ray reduced 5-methylcytosine levels by about 50% within a 
few days in cell lines (Kalinich et al., 1989). In mice irradiated with 4, 7 and 10 
Gy of X-ray, the 5-methylcytosine levels were decreased at 3 days (Tawa et al., 
1998). In line with previous reports, the DNA methylation levels of C1S2 in 
A549 cells (Fig. 11B) were downregulated at 3 days after IR with different doses 
of X-ray (4, 6, and 10 Gy). 
             
Fig. 11A. Hypoxia induces demethylation of C1S2 repetitive elements. 
Bisulfite-modified genomic DNA was isolated from CoCl2-treated cells and 
amplified by PCR following digestion with HinfI, which only cuts methylated 
repetitive elements. +, CoCl2 treated; -, no CoCl2 treated; u, unmethylated 
products; m, methylated products. M, 100 bp marker. 
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Fig. 11B. Dose-response of IR-induced reduction of DNA methylation levels 
in A549 cells. A549 cells were irradiated with 0, 4, 6 and 10 Gy and the DNA 
methylation level at 3 days after IR was determined by COBRA using specific 
primers for amplification of C1S2. 
 
4.3. Effect of 53BP1 on global DNA demethylation  
To test the hypothesis that 53BP1 might be involved in the induction of DNA 
demethylation, we employed COBRA to analyze the DNA methylation status of 
C1S2 in A549 cells transfected with 53BP1. As shown in Fig. 12A, high level of 
methylation was revealed in control A549 cells while DNA demethylation was 
found in A549 cells with 53BP1-overexpression, especially upon transfection 
with full -length 53BP1. Therefore, 53BP1 is able to induce DNA demethylation 
of global DNA. Furthermore, IR can induce DNA demethylation as described 
previously (Tawa et al., 1998; Koturbash et al., 2005) and may enhance the 
demethylating effect of 53BP1 in A549 cells (Fig. 12B). 
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Fig. 12. 53BP1 promotes global demethylation.  
COBRA analysis of C1S2 CpG dinucleotides in A549 cells transfected with 
indicated plasmids (A) and in irradiated cells (6 Gy) at 24 h after transfection (B). 
Genomic DNA was isolated 72 h later. Bisulfite-modified DNA was amplified 
using COBRA with specific primers for C1S2. u, unmethylated products; m, 
methylated products. Full, cells transfected with full-length of 53BP1; N, cells 
transfected with N-terminal of 53BP1; C, cells transfected with C-terminal of 
53BP1; Con, cells transfected with control plasmid. M, 100 bp marker.  
 
 
 
4.4. Effect of 53BP1 on DNA demethylation of specific gene. 
The RASSF1A has been reported to be inactivated by hypermethylation in the 
promoter in many types of cancer and cancer cell lines including A549 cells 
(Dammann et al., 2002; Kuzmin et al., 2002; Mund et al., 2005). The methylation 
status of the promoter of RASSF1A in cells transfected with 53BP1 was analyzed 
by MSP. Only the methylated sequence was detected in control A549 cells (Fig. 
13A). In contrast, increasing demethylation products were revealed in A549 cells 
transfected with 53BP1 after 3 days. Similar results were obtained from irradiated 
cells (6 Gy) at 24 h after transfection (Fig. 13B). These findings indicate that 
53BP1 is able to induce DNA demethylation of specific gene. 
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Fig. 13. 53BP1 promotes gene-specific DNA demethylation.  
MSP analysis of RASSF1A in A549 cells transfected with indicated plasmids (A) 
and in irradiated cells (6 Gy) at 24 h after transfection (B). Genomic DNA was 
isolated 72 h later. Bisulfite-modified DNA was analyzed using MSP. Full, cells 
transfected with full-length of 53BP1; N, cells transfected with N-terminal of 
53BP1; C, cells transfected with C-terminal of 53BP1; Con, cells transfected with 
control plasmid. M, 100 bp marker; u, unmethylated products; m, methylated 
products. 
 
 
4.5. Effect of 53BP1 on re-expression of specific gene 
Consistent with the increase in unmethylated products of its promoter, the 
transcriptional expression of RASSF1A gene was detectable in A549 cells after 
transfection with 53BP1 by RT-PCR (Fig. 14). These results confirmed that loss 
of RASSF1A transcription correlated with hypermethylation of its CpG islands in 
the promoter and indicated the effect of 53BP1 on DNA demethylation of 
RASSF1A.  
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Fig. 14. Effect of 53BP1 on re-expression of RASSF1A. The expression of 
RASSF1A was analyzed in A549 cells transfected with indicated plasmids after 3 
days. GAPDH was used as an external control. Full, cells transfected with 
full-length of 53BP1; N, cells transfected with N-terminal of 53BP1; C, cells 
transfected with C-terminal of 53BP1; Con, cells transfected with control plasmid 
M, 100 bp marker. Hela, Hela cells, that contains unmethylated RASSF1A gene, 
was used as positive control for the expression of RASSF1A. 
 
4.6. Transcriptional levels of relative genes in 53BP1-transfected 
A549 cells 
To gain insight into the potential mechanism responsible for 53BP1-induced 
demethylation, we addressed a number of DNA methylases and demethylases that 
can serve as determinants of DNA methylation status. The effect of 53BP1 on the 
transcriptional expression of human DNMT1, DNMT3a, DNMT3b, MBD2 and 
Gadd45a was investigated by real-time PCR. As shown in Fig. 15A, real-time 
PCR revealed 3-fold, 13-fold, 13.9-fold up-regulation in Gadd45a mRNA 
expression level in A549 cells following transfection with N-terminal, C-terminal, 
and full-length of 53BP1, respectively. Furthermore, IR induced a 26-fold 
up-regulation of Gadd45a in control A549 cells and a 36-fold up-regulation in 
A549 cells transfected with full-length-53BP1. These findings implicate a 
potential role for Gadd45a regarding 53BP1-induced demethylation in A549 cells 
response to DNA damage. The effect of 53BP1 on the expression of MBD2 was 
also determined. As shown in Fig. 15B, real-time PCR revealed a 5.1-fold, 
6.5-fold up-regulation in MBD2 expression level of A549 cells following 
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transfection with full-length and C-terminal of 53BP1. In contrast, N-terminal of 
53BP1 did not affect the expression level of MBD2 (0.95-fold). Other critical 
determinants of DNA methylation are DNMTs. Real time PCR analysis revealed 
a 0.5-fold, 0.6-fold and 0.7-fold decrease in the mRNA level of DNMT1 in A549 
cells following transfection with full-length, N-terminal, and C-terminal of 
53BP1, respectively (Fig. 15C). In addition, a 0.1-fold, 0.06-fold, 0.06-fold 
decrease in DNMT3a level was detected in A549 cells following transfection 
with full-length, N-terminal, and C-terminal of 53BP1, respectively (Fig. 15D). 
These results indicated that 53BP1 could down regulate the expression of 
DNMT1 and DNMT3a. In contrast, increased expression of DNMT3b (10-fold, 
3-fold and 2-fold) was found in A549 cells following transfection with full-length, 
N-terminal, and C-terminal of 53BP1, respectively (Fig. 15E). These results 
suggest that DNMTs and MBD2 might have functional relevance in the pathway 
of 53BP1-induced DNA demethylation. 
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Fig. 15. The expression levels of A). Gadd45a in 53BP1-transfected and/or 
irradiated A549 cells. A549 cells were exposed to 6 Gy IR at 24 h after 
transfection. +, with IR; －, without IR. The expression levels of B). MBD2, C). 
DNMT1, D). DNMT3a and E). DNMT3b in 53BP1-transfected A549 cells. 
Real time PCR was performed 72 h after transfection. Data represent mean ± SE 
derived from three independent experiments.  
 
 
 43 
5. Discussion 
In this study, the functions of 53BP1 in DNA demethylation and the expression 
changes of DNMTs, Gadd45a, and MBD2 induced by 53BP1 were examined in 
A549 cells. To the author’s best knowledge, we provide the first evidence of 
involvement of 53BP1 in DNA demethylation process in tumor cells. 
 
5.1. 53BP1 overexpression can promote global DNA 
demethylation and reactivate specific methylation-silenced gene 
53BP1 has been suggested as a sensor and/or mediator of the DNA damage 
checkpoint in response to IR (Schultz et al., 2000; Peng et al., 2003; Wilson et al., 
2008). The latter, in turn, has been previously shown to induce DNA 
demethylation (Tawa et al., 1998; Koturbash et al., 2005). In the present study, 
we focused on the possible functions of 53BP1 involved global DNA 
demethylation as well as gene specific demethylation. Analyzing the methylation 
of repetitive elements can serve as a surrogate marker for global genomic DNA 
methylation  (Yang et al., 2004; Kim et al., 2007; Qin et al., 2007; Wilson et al., 
2007). Because the repetitive elements C1S2 is frequently hypermethylated in its 
CpG dinucleotides in diverse cells, the effect of 53BP1 on this marker in A549 
cells was analyzed using COBRA in this study. Interestingly, the overexpression 
of full-length cDNA as well as both N-terminal and C-terminal of 53BP1 can 
induce demethylation of the repetitive elements C1S2 in A549 cells.  
 
Several recent studies have provided compelling evidence linking DNA 
methylation to transcriptional suppression of specific genes (Di Croce et al., 2002; 
Brenner et al., 2005; Esteve et al., 2005). RASSF1A is a candidate tumor 
suppressor gene that has recently been shown to be inactivated by methylation in 
many types of cancer and tumor cells including A549 cells (Beaulieu et al., 2002; 
Dammann et al., 2005a. b). In line with previous reports, the promoter region of 
RASSF1A was methylated in A549 cells resulting in transcriptional silence in 
this study. The overexpression of the full-length cDNA as well as both 
N-terminal and C-terminal of 53BP1 resulted in different intensities of DNA 
demethylation and restored the expression of this silenced gene analyzed by MSP 
and RT-PCR. Furthermore, we demonstrated that 53BP1 overexpression could 
 44 
enhance DNA demethylation after DNA damage induced by irradiation, 
suggesting that 53BP1 may contribute to both IR induced DNA repair and DNA 
demethylation. 
 
5.2. 53BP1-induced DNA demethylation is associated with 
DNMTs 
Recent studies have demonstrated that the DNA methylation mediated by DNMTs 
is associated with p53 signalling in maintaining genome stability. The 
hypermethylation patterns in cancers have been suggested to be associated with 
altered changes in the DNA methylation enzymes. Several lines of evidence have 
suggested that 53BP1 mediated demethylation may be involved in the regulation 
of DNMTs activities: 1) p53 and DNMT1 cooperate to repress survivin gene 
expression (Esteve et al., 2005); 2) DNMT3a interacts with p53 and represses 
p53-mediated gene expression (Wang et al., 2005); 3) in vivo reporter assay 
demonstrates that 53BP1 can enhance p53-mediated transcriptional activation 
(Iwabuchi et al., 1998; Zhang et al., 2006; Huang et al., 2007). In this study, the 
expression of different DNMTs in response to overexpression of 53BP1 was 
investigated. The overexpression of 53BP1 resulted in upregulation of DNMT3b 
mRNA level. In contrast, 53BP1 gain-of-function significantly downregulated 
DNMT1 and DNMT3a transcriptional expression. It is surprising when 
considering the fact that both enzymes are de novo methyltransferases. It is 
noteworthy to mention that mice embryos lacking both copies of DNMT3b die 
before birth, whereas DNMT3a-null mice survive for about 4 weeks (Okano et al., 
1999). DNMT3b has significant site selectivity that is distinct from DNMT1 
(Beaulieu et al., 2002). A possible explanation for the discrepancy in the present 
results is that these enzymes may have distinct cell- or tissue-specific function as 
previously suggested (Bestor TH, 2000). In this respect, further studies of the 
interaction between 53BP1 and DNMTs are necessary to clarify the mechanisms 
of 53BP mediated DNA demethylation in different types of cells.  
 45 
5.3. 53BP1 induces the activation of Gadd45a  
Gadd45 plays important role in different biological processes including the 
maintenance of genomic stability, cell growth control, NER, chromatin 
accessibility and apoptosis (Smith et al., 1994; Smith et al., 2000; Hollander et al., 
2001; Smith et al., 2002; Zhan et al., 2005). Barreto et al have revealed that 
Gadd45a is a key regulator of active DNA demethylation and it acts by promoting 
DNA repair, thus linking both processes (Barreto et al., 2007). The transcriptional 
activation of GADD45a is regulated by BRCA1 and p53, a downstream target of 
53BP1, in cellular DNA damage (Wang et al., 1999). This suggests possible 
effects of 53BP1 in the transcriptional regulation of Gadd45a. In this study, the 
expression changes of Gadd45a induced by the overexpression of 53BP1 were 
analyzed. A remarkable increase in the transcriptional level of Gadd45a was 
found in cells expressing 53BP1. Furthermore, we have found that 53BP1 can 
enhance the up-regulation of Gadd45a in A549 cells exposed to IR. These data 
presented here suggest that 53BP1-induced DNA demethylation might be 
mediated by activation of Gadd45a. 
 
5.4. 53BP1 induces the activation of MBD2 
MBD2 has been described as a DNA demethylase (Bhattacharya et al., 1999; 
Detich et al., 2002, 2003). Szyf and his colleagues have reported that MBD2 
purified from A549 cells is a demethylase that can transform a methyl cytosine in 
DNA to cytosine (Ramchandani et al., 1999; Bhattacharya et al., 1999). On the 
other hand, MBD2 is part of the methylated gene-repression MeCP1 complex 
(Stirzaker et al., 2004; David et al., 2004; Lin et al., 2003; Bakker et al., 2002, 
Patra et al., 2008) and has functions as a typical methylated DNA binding protein 
by recruitment of the chromatin remodeling complexes containing HDACs to 
methylated DNA (Ng et al., 1999; Wade et al., 1999). In this study, we 
demonstrated increased expression of MBD2 in response to overexpression of 
53BP1 in A549 cells, suggesting a possible involvement of MBD2 in DNA 
demethylation induced by 53BP1. Noteworthy, the expression of N-terminal of 
53BP1 could not regulate the transcriptional level of MBD2, whereas the 
expression of C-terminal and full-length cDNA of 53BP1 enhanced the mRNA 
expression level analyzed by RT-PCR. This discrepancy suggested that the 
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C-terminal 700 amino acids of 53BP1 encode important functional domains 
(Jullien et al., 2002; Iwabuchi et al., 2003; Koonin et al., 1996) to regulate the 
transcriptional level of MBD2. The genetic knock out mice with truncated 53BP1, 
lacking functional domains on C-terminal, has been reported to show a 53BP1 
knockout phenotype (Morales et al., 2003), highlighting the importance of these 
domains on the C-terminal of 53BP1 and supporting our data in this study. 
 
5.5. A suggested role of 53BP1 in DNA demethylation 
Carcinogenesis can result from aberrations in genomic DNA methylation such as 
hypermethylation or hypomethylation of the promoter or the first exon in 
tumor-related genes. Hypermethylation of CpG islands associated expression 
silence of tumor suppressor genes has been proposed to contribute to 
carcinogenesis (Baylin et al., 2000; Andrew et al., 2004; Esteller M, 2007; Jones 
et al., 2007). The 53BP1 protein stands out as a prime model of a damage signal 
sensor and/or mediator in DDR (Wang et al., 2002), one of the cardinal processes 
for maintaining cellular homeostasis and keeping the cell from taking the 
neoplastic path (Phillips and McKinnon 2007; d'Adda di Fagagna, 2008). 
Furthermore, the DDR signifies a crossroads at which tissue development, ageing 
and cancer converge. Our data in present study point to 53BP1 function in DNA 
demethylation. However, how 53BP1 regulates different member of DNMT need 
to be characterized. Further experiments of the precise mechanisms of 53BP1 in 
DNA demethylation may clarify this association and develop therapeutic 
alternatives designed to promote hypomethylation and re-activation of tumor 
suppressor genes. These results in present study reveal a novel function of 
53BP1in regulation of DNA demethylation. A model for the role of 
53BP1-induced DNA demethylation is suggested. 
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Fig. 18. A suggested model for the role of 53BP1 in DNA demethylation. 
The possible signalling pathways of 53BP1 in the regulation of DNA 
demethylation are depicted.  
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6. Summary 
 
DNA damage can be caused by various forms of genotoxic stress, including 
endogenous (reactive oxygen species, abnormal replication intermediates) and 
exogenous (UV, IR, and reactive chemicals) sources. DNA double-strand break 
(DSB) is believed to be one of the most serious lesions to cells because it can 
result in loss or rearrangement of genetic information, leading to cell death or 
carcinogenesis. The DNA damage response (DDR) involves multiple signal 
transduction pathways in that several different components act in concert to 
activate the cellular checkpoint. These components consist of sensors that sense 
DNA damage, signal transducers that generate and amplify the DNA damage 
signal, and effectors that induce cell cycle delay, programmed cell death, and 
DNA repair. 
 
Even though several candidate proteins have been implicated in DNA damage 
response, an official checkpoint-specific damage sensor is still unknown. 53BP1 
seems to be one of the key-sensors of DNA DSBs, upstream of ATM. The 
function of 53BP1 is important for coupling ATM to its downstream targets, 
including p53 and Gadd45a. The activation of Gadd45a as a stress protein 
promotes epigenetic gene activation by repair-mediated DNA demethylation, thus 
linking both processes. DNA methylation is mediated by MBD2 as well as a class 
of DNMTs, which encompassing DNMT1, DNMT3a and DNMT3b. Recent 
studies have demonstrated that the DNA methylation mediated by DNMTs is 
associated with p53 signalling in maintaining genome stability. Since p53 is one 
of the downstream targets of 53BP1, it will be of interest to investigate the 
functions of 53BP1 in DNA demethylation and determine the possible link 
between 53BP1 and these related genes.  
 
The data presented here indicate that 53BP1 can induce DNA demethylation of 
single copy gene as well as repetitive elements in A549 cells. Meanwhile, the 
transient expression of 53BP1 can enhance DNA demethylation in combination 
with IR. Furthermore, the tumor suppressor gene RASSF1A was re-expressed 
following predominantly demethylation of CpG islands in the promoter analyzed 
by MSP and RT-PCR. Moreover, overexpression of 53BP1 caused a marked 
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decrease in DNMT1 and DNMT3a mRNA expression as well as a significant 
increase in Gadd45a and MBD2 mRNA expression. To our best knowledge, the 
present study shows for the first time the involvement of 53BP1 in DNA 
demethylation process. Understanding the 53BP1-mediated network will certainly 
have an impact on numerous fields of medicine. However, how 53BP1 regulates 
different member of DNMTs need to be characterized. Further experiments of the 
precise mechanisms of 53BP1 in DNA demethylation may clarify this association 
and develop therapeutic alternatives designed to promote hypomethylation and 
re-activation of tumor suppressor genes. 
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6. Zusammenfassung 
 
Der DNA-Schaden kann durch verschiedene Formen von genotoxischem Stress, 
inklusive endogenen (reaktive Sauerstoffrradikale, irreguläre Replikations- 
produkte) sowie exogenen (UV- und ionisierende Strahlung, reaktive 
Chemikalien) Faktoren verursacht werden. Ein DNA-Doppelstrangbruch (DSB) 
ist einer der schwerwiegendsten DNA-Schäden in der Zelle und kann zur 
Veränderung genetischen Information, Auslösung einer Reparaturantwort oder 
zum Zelltod bzw. Karzinogenese führen. Die Zellantwort auf dem DNA-Schaden 
involviert mehrere Signaltransduktionswege, in dem mehrere verschiedene 
Komponenten zur Aktivierung der Zellkontrollpunkte zusammen wirken. Die 
Komponenten bestehen aus den Sensoren, den Signaltransduktoren, welche das 
DNA-Schadenssignal erkennen und amplifizieren sowie den Effektoren, die den 
Zellzyklusarrest, den programmierten Zelltod und die DNA-Reparatur induzieren. 
 
Zwar sich an der Zellantwort des DNA-Schadens mehre Kandidatproteine 
beteiligen, ist ein spezifischer Sensor für die zelluläre Schadensantwort noch 
unbekannt. Das funktionelle „upstream“ Protein von ATM/ATR, 53BP1, hat sich 
als einer der Sensoren für DNA-DSB, herausgestellt und spielt eine wichtige 
Rolle bei der Anbindung des ATM zu seinen abwärts Targetproteinen inklusive 
p53 und Gadd45. Die Aktivierung des Gadd45 Proteins führt zur epigenetischen 
Genaktivierung durch die Reparatur-vermittelte DNA-Demethylierung und 
verbindet beide Prozesse. Die DNA Methylierung wird durch MBD2 sowie eine 
Klasse von DNMTs, welche DNMT1, DNMT3a und DNMT3b einschließen, 
vermittelt. Neue Studien haben gezeigt, dass die DNMTs-vermittelte DNA 
Methylierung assoziiert mit dem p53 Signaltransdutionsweg zur Beibehaltung der 
Genomstabilität ist. Da p53 eines der abwärts gelegenen Targetgene vom 53BP1 
ist, wird es von Interesse sein, um die Funktionen 53BP1 in der 
DNA-Demethylierung zu untersuchen und die mögliche Verbindung zwischen 
53BP1 und diese zusammenhängenden Gene zu bestimmen.  
 
Die experimentiellen Daten der vorliegenden Arbeit haben gezeigt, dass die 
transiente Expression des 53BP1 in A549 Zellen die DNA-Demethylierung von 
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einzelnen Kopiegenen sowie repetitiven Elementen induzieren konnte. 
Desweiteren konnte 53BP1 die DNA-Demethylierung durch ionisierte Strahlung 
erhöhen. mit Hilfe der MSP und RT-PCR konnte die Demethylierung dessen 
Promoters und Reaktivierung des silenten Tumorsuppressorgens RASSF1A 
untersucht werden. Ausserdem führte die Überexpression von 53BP1 zu einer 
signifikant reduzierten Expression von DNMT1 und DNMT3a sowie erhörten 
Expression von Gadd45a und MBD2. Es ist das erste Mal gezeigt worden, dass 
53BP1 in der DANN-Demethylierung beteiligt sein könnte. Weitere Experimente 
werden durchgeführt werden müssen, um die genauen Mechanismen des 53BP1 
bei der DNA-Methylierung zu klären und therapeutische Alternativen zu 
entwickeln, die die Demethylierung und Reaktivierung von 
Tumorsuppressorgenen fördern. 
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8. Attachment 
8.1. Abbreviation 
ATC American Type Culture Collection 
ATM kinase ataxia-telangeictasia-mutated 
ATR ataxia telangiectasia and rad3-related 
Bp base pair  
CHK1 Checkpoint Kinase 1 
CDNA complementary DNA 
CHK2 Checkpoint Kinase 2 
C1S2 chromosome 1 satellite 2 
DDR DNA damage response 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
DNMTs DNA methyltransferases 
DSBs DNA double-strand breaks 
dNTPs deoxynucleotide triphosphates 
EB ethidium bromide 
EDTA ethylene diamine tetraacetic acid 
FBS fetal bovine serum 
Gadd gene DNA damage-inducible gene 
GAPDH Glyseraldehyde-3-phosphate dehydrogenase 
HAT histone acetyl transferases 
HDACs histone deacetylases 
IR irradiation 
NER nucleotide excision repair 
Nt nucleotide 
OD optical density 
PBS phosphate-buffered saline 
PCNA proliferating cell nuclear antigen 
PCR polymerase chain reaction 
Rmp round per minute 
RNA ribonucleic acid 
RT room temperature 
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RT-PCR reverse transcription PCR 
SAM S-adenosylmethionine 
SAH S-adenosylhomocysteine 
TAF Trans-acting activating factors 
TBE Tris-boric acid, EDTA buffer 
TEMED N,N,N’,N’-Tetraethylendiamin 
TFs transcription factors 
TR trans-acting repressors 
Tris Tris (hydroxymethyl) aminomethane 
UV ultraviolet radiation 
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